H. Lundbeck AS (HLu)
Company websiteKarina Fog, PhD, Senior director
Neuroscience Research, Protein Aggregation, Folding and Clearance
H. Lundbeck A/S
Ottiliavej 9
2500 Valby, Copenhagen
DK – Denmark
Kape at Lundbeck.com
Karina Fog, M.Sc, Ph.D, Senior Director, Neuroscience Research, Protein Aggregation, Folding and Clearance, H. Lundbeck A/S. Currently leading the Biology focus area; Protein Aggregation, Folding & Clearance being strategic responsible for the Research portfolio within this area and member of the Research management team.
Twentynine years' experience in Drug Discovery within the Pharmaceutical Industry with extensive knowledge on the full value chain in Drug Discovery from Research to Marketing. Has primarily focused on preclinical research to generate the evidence to support the development of new potential treatments of diseases in the central nervous system, in particular the Neurodegenerative diseases, Parkinson's disease and Alzheimer's disease. Has during the past seventeen years as head of department gained strong expertise in scientific as well as people management and with the group delivered six programs to clinical development. Is cell biologist of training and expert in the biology of neurodegenerative diseases associated with protein aggregation/misfolding (in particular alpha-synuclein). Has over the years had a particular focus on establishing cellular model systems with disease relevant phenotypes/ endpoints and using these for target finding, target validation and profiling of efficacy of new potential drug candidates. Is inventor on Lundbeck’s first in-house developed therapeutic antibody targeting alpha-synuclein, planned to enter phase 3 clinical trial in Multiple system atrophy. Strong external engagement in work facilitating collaborations across academia and industry. For example by promoting open innovation platforms in drug discovery, participating in EU consortia's or advising academic research on commercialization of research results.
In Lundbeck Research we are a big team of app 220 employees that work together cross-functionally to develop either small molecule or biologics as potential drugs. We generate hypothesis and develop biological model systems to validate the strength of a given target for the potential treatment of brain disease and have strong focus on innovation.
H. Lundbeck A/S is a pharmaceutical company based in Copenhagen, Denmark. The company focuses on developing treatments for diseases of the central nervous system and has pioneered some of the most important and commonly used therapies within antipsychotics and antidepressants. Our products are registered in 100 countries globally and in average 8 million people are treated with our products on a daily basis. All disciplines of the full Drug Discovery pipeline; Research, Development, Production, Sales and Marketing are represented at headquarters in Copenhagen. The Lundbeck Foundation is the majority owner of Lundbeck and the ownership by the Foundation allows the company to stay focused on areas of specialization within Brain diseases. There are currently 5,400 employees in the company.